Silo Pharma issues shareholder letter: SPC-15 IND expected 2025, SP-26 animal studies in early 2025

Silo Pharma, Inc.

IND submission for SPC-15 intranasal PTSD treatment expected in 2025; Phase 1 trial to follow upon FDA approval.
SP-26 ketamine implant for fibromyalgia nearing first animal studies in early 2025; aims for at-home injectable therapeutic.
Both SPC-15 and SP-26 may qualify for FDA's streamlined 505(b)(2) approval pathway, reducing costs and time.
Cash on hand and minimal debt provide financial flexibility; no specific financial guidance disclosed.
Exclusive global license from Columbia University for SPC-15 pre-clinical development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.